nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP3A4—bone cancer	0.703	1	CbGaD
Paricalcitol—VDR—periosteum—bone cancer	0.0118	0.194	CbGeAlD
Paricalcitol—VDR—vertebral column—bone cancer	0.00978	0.161	CbGeAlD
Paricalcitol—VDR—leg—bone cancer	0.00941	0.155	CbGeAlD
Paricalcitol—VDR—forelimb—bone cancer	0.00934	0.154	CbGeAlD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00882	0.0956	CbGpPWpGaD
Paricalcitol—VDR—hindlimb—bone cancer	0.00841	0.138	CbGeAlD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.00774	0.0839	CbGpPWpGaD
Paricalcitol—VDR—appendage—bone cancer	0.00721	0.119	CbGeAlD
Paricalcitol—VDR—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00695	0.0753	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00476	0.0516	CbGpPWpGaD
Paricalcitol—VDR—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00406	0.044	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00399	0.0433	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00379	0.0411	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—NR1I2—bone cancer	0.00365	0.0396	CbGpPWpGaD
Paricalcitol—UGT1A4—Tamoxifen metabolism—CYP3A4—bone cancer	0.00327	0.0355	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00303	0.0329	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00289	0.0313	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00278	0.0302	CbGpPWpGaD
Paricalcitol—UGT1A4—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00234	0.0253	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00233	0.0253	CbGpPWpGaD
Paricalcitol—VDR—connective tissue—bone cancer	0.00206	0.0338	CbGeAlD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00177	0.0192	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00174	0.0189	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDK4—bone cancer	0.00152	0.0165	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.0015	0.0163	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—ZNF77—bone cancer	0.00147	0.016	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00143	0.0155	CbGpPWpGaD
Paricalcitol—VDR—tendon—bone cancer	0.00141	0.0233	CbGeAlD
Paricalcitol—VDR—bone marrow—bone cancer	0.00137	0.0225	CbGeAlD
Paricalcitol—Calcitriol—CYP3A4—bone cancer	0.00125	0.416	CrCbGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00114	0.0124	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00108	0.0117	CbGpPWpGaD
Paricalcitol—Ergocalciferol—CYP3A4—bone cancer	0.001	0.332	CrCbGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTP1—bone cancer	0.000889	0.00964	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.000827	0.00897	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP3A4—bone cancer	0.000761	0.00825	CbGpPWpGaD
Paricalcitol—Cholecalciferol—CYP3A4—bone cancer	0.00076	0.252	CrCbGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP3A4—bone cancer	0.00075	0.00813	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—MDM2—bone cancer	0.00074	0.00802	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000722	0.00783	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ZNF77—bone cancer	0.000709	0.00769	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000698	0.00756	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTP1—bone cancer	0.000651	0.00705	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTP1—bone cancer	0.000642	0.00696	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000618	0.0067	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP3A4—bone cancer	0.000608	0.00659	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP3A4—bone cancer	0.0006	0.0065	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GSTP1—bone cancer	0.000593	0.00643	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—TGFBR2—bone cancer	0.000593	0.00643	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000549	0.00595	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTP1—bone cancer	0.00052	0.00564	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTP1—bone cancer	0.000513	0.00556	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—NR1I2—bone cancer	0.000499	0.0054	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000492	0.00534	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MET—bone cancer	0.000466	0.00505	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000465	0.00504	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NDUFA12—bone cancer	0.000456	0.00494	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—RB1—bone cancer	0.000405	0.00439	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MMP2—bone cancer	0.000389	0.00421	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NT5C3A—bone cancer	0.000378	0.0041	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NDUFA12—bone cancer	0.000365	0.00395	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—FUS—bone cancer	0.000346	0.00375	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MDM2—bone cancer	0.000346	0.00374	CbGpPWpGaD
Paricalcitol—Decreased appetite—Cisplatin—bone cancer	0.000308	0.00219	CcSEcCtD
Paricalcitol—Pneumonia—Methotrexate—bone cancer	0.000306	0.00218	CcSEcCtD
Paricalcitol—Nasopharyngitis—Doxorubicin—bone cancer	0.000306	0.00218	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Cisplatin—bone cancer	0.000306	0.00217	CcSEcCtD
Paricalcitol—Infestation NOS—Methotrexate—bone cancer	0.000305	0.00217	CcSEcCtD
Paricalcitol—Infestation—Methotrexate—bone cancer	0.000305	0.00217	CcSEcCtD
Paricalcitol—Depression—Methotrexate—bone cancer	0.000304	0.00216	CcSEcCtD
Paricalcitol—Gastritis—Doxorubicin—bone cancer	0.000303	0.00215	CcSEcCtD
Paricalcitol—Pain—Cisplatin—bone cancer	0.000303	0.00215	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—NT5C3A—bone cancer	0.000302	0.00327	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—JUN—bone cancer	0.0003	0.00326	CbGpPWpGaD
Paricalcitol—Upper respiratory tract infection—Epirubicin—bone cancer	0.000297	0.00211	CcSEcCtD
Paricalcitol—Conjunctivitis—Methotrexate—bone cancer	0.000296	0.00211	CcSEcCtD
Paricalcitol—Dysphagia—Doxorubicin—bone cancer	0.000296	0.0021	CcSEcCtD
Paricalcitol—Asthma—Doxorubicin—bone cancer	0.000296	0.0021	CcSEcCtD
Paricalcitol—Influenza—Doxorubicin—bone cancer	0.000296	0.0021	CcSEcCtD
Paricalcitol—Sweating—Methotrexate—bone cancer	0.000292	0.00208	CcSEcCtD
Paricalcitol—Feeling abnormal—Cisplatin—bone cancer	0.000292	0.00207	CcSEcCtD
Paricalcitol—Pancreatitis—Doxorubicin—bone cancer	0.00029	0.00206	CcSEcCtD
Paricalcitol—Weight decreased—Epirubicin—bone cancer	0.000289	0.00206	CcSEcCtD
Paricalcitol—Epistaxis—Methotrexate—bone cancer	0.000287	0.00204	CcSEcCtD
Paricalcitol—Pneumonia—Epirubicin—bone cancer	0.000287	0.00204	CcSEcCtD
Paricalcitol—Infestation NOS—Epirubicin—bone cancer	0.000285	0.00203	CcSEcCtD
Paricalcitol—Infestation—Epirubicin—bone cancer	0.000285	0.00203	CcSEcCtD
Paricalcitol—Body temperature increased—Cisplatin—bone cancer	0.00028	0.00199	CcSEcCtD
Paricalcitol—Urinary tract infection—Epirubicin—bone cancer	0.000277	0.00197	CcSEcCtD
Paricalcitol—Conjunctivitis—Epirubicin—bone cancer	0.000277	0.00197	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000275	0.00196	CcSEcCtD
Paricalcitol—Sweating—Epirubicin—bone cancer	0.000273	0.00194	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—bone cancer	0.000271	0.00193	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—bone cancer	0.00027	0.00192	CcSEcCtD
Paricalcitol—Epistaxis—Epirubicin—bone cancer	0.000269	0.00191	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—bone cancer	0.000268	0.00191	CcSEcCtD
Paricalcitol—Weight decreased—Doxorubicin—bone cancer	0.000268	0.0019	CcSEcCtD
Paricalcitol—Sinusitis—Epirubicin—bone cancer	0.000268	0.0019	CcSEcCtD
Paricalcitol—Pneumonia—Doxorubicin—bone cancer	0.000265	0.00189	CcSEcCtD
Paricalcitol—Infestation—Doxorubicin—bone cancer	0.000264	0.00188	CcSEcCtD
Paricalcitol—Infestation NOS—Doxorubicin—bone cancer	0.000264	0.00188	CcSEcCtD
Paricalcitol—Hypersensitivity—Cisplatin—bone cancer	0.000261	0.00186	CcSEcCtD
Paricalcitol—Conjunctivitis—Doxorubicin—bone cancer	0.000256	0.00182	CcSEcCtD
Paricalcitol—Urinary tract infection—Doxorubicin—bone cancer	0.000256	0.00182	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—bone cancer	0.000256	0.00182	CcSEcCtD
Paricalcitol—Hypoaesthesia—Epirubicin—bone cancer	0.000255	0.00181	CcSEcCtD
Paricalcitol—Asthenia—Cisplatin—bone cancer	0.000254	0.00181	CcSEcCtD
Paricalcitol—Pharyngitis—Epirubicin—bone cancer	0.000254	0.00181	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—bone cancer	0.000254	0.0018	CcSEcCtD
Paricalcitol—Sweating—Doxorubicin—bone cancer	0.000253	0.0018	CcSEcCtD
Paricalcitol—Urinary tract disorder—Epirubicin—bone cancer	0.000253	0.0018	CcSEcCtD
Paricalcitol—Oedema peripheral—Epirubicin—bone cancer	0.000252	0.00179	CcSEcCtD
Paricalcitol—Connective tissue disorder—Epirubicin—bone cancer	0.000252	0.00179	CcSEcCtD
Paricalcitol—Urethral disorder—Epirubicin—bone cancer	0.000251	0.00178	CcSEcCtD
Paricalcitol—Epistaxis—Doxorubicin—bone cancer	0.000249	0.00177	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—bone cancer	0.000248	0.00176	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—bone cancer	0.000248	0.00176	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—bone cancer	0.000247	0.00176	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—bone cancer	0.000247	0.00175	CcSEcCtD
Paricalcitol—Chills—Methotrexate—bone cancer	0.000245	0.00174	CcSEcCtD
Paricalcitol—Diarrhoea—Cisplatin—bone cancer	0.000242	0.00172	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—bone cancer	0.000242	0.00172	CcSEcCtD
Paricalcitol—VDR—Gene Expression—NR1I2—bone cancer	0.00024	0.0026	CbGpPWpGaD
Paricalcitol—Mental disorder—Methotrexate—bone cancer	0.00024	0.0017	CcSEcCtD
Paricalcitol—Eye disorder—Epirubicin—bone cancer	0.000239	0.0017	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—bone cancer	0.000238	0.00169	CcSEcCtD
Paricalcitol—Cardiac disorder—Epirubicin—bone cancer	0.000238	0.00169	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—EGFR—bone cancer	0.000236	0.00256	CbGpPWpGaD
Paricalcitol—Hypoaesthesia—Doxorubicin—bone cancer	0.000236	0.00168	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—bone cancer	0.000235	0.00167	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—bone cancer	0.000234	0.00166	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—bone cancer	0.000233	0.00166	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—bone cancer	0.000233	0.00166	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—bone cancer	0.000233	0.00165	CcSEcCtD
Paricalcitol—Angiopathy—Epirubicin—bone cancer	0.000232	0.00165	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—bone cancer	0.000232	0.00165	CcSEcCtD
Paricalcitol—Immune system disorder—Epirubicin—bone cancer	0.000231	0.00164	CcSEcCtD
Paricalcitol—Mediastinal disorder—Epirubicin—bone cancer	0.000231	0.00164	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—bone cancer	0.00023	0.00164	CcSEcCtD
Paricalcitol—Chills—Epirubicin—bone cancer	0.00023	0.00163	CcSEcCtD
Paricalcitol—Arrhythmia—Epirubicin—bone cancer	0.000229	0.00163	CcSEcCtD
Paricalcitol—Alopecia—Epirubicin—bone cancer	0.000226	0.00161	CcSEcCtD
Paricalcitol—Vomiting—Cisplatin—bone cancer	0.000225	0.0016	CcSEcCtD
Paricalcitol—Mental disorder—Epirubicin—bone cancer	0.000224	0.00159	CcSEcCtD
Paricalcitol—Rash—Cisplatin—bone cancer	0.000223	0.00159	CcSEcCtD
Paricalcitol—Dermatitis—Cisplatin—bone cancer	0.000223	0.00159	CcSEcCtD
Paricalcitol—Malnutrition—Epirubicin—bone cancer	0.000223	0.00158	CcSEcCtD
Paricalcitol—Eye disorder—Doxorubicin—bone cancer	0.000221	0.00157	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—bone cancer	0.000221	0.00157	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—bone cancer	0.00022	0.00156	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—bone cancer	0.00022	0.00156	CcSEcCtD
Paricalcitol—Tension—Epirubicin—bone cancer	0.000219	0.00155	CcSEcCtD
Paricalcitol—Dysgeusia—Epirubicin—bone cancer	0.000218	0.00155	CcSEcCtD
Paricalcitol—Nervousness—Epirubicin—bone cancer	0.000216	0.00154	CcSEcCtD
Paricalcitol—Back pain—Epirubicin—bone cancer	0.000216	0.00153	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—bone cancer	0.000215	0.00153	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—bone cancer	0.000215	0.00153	CcSEcCtD
Paricalcitol—Muscle spasms—Epirubicin—bone cancer	0.000214	0.00152	CcSEcCtD
Paricalcitol—Immune system disorder—Doxorubicin—bone cancer	0.000214	0.00152	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—bone cancer	0.000214	0.00152	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—bone cancer	0.000213	0.00152	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—bone cancer	0.000213	0.00152	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—bone cancer	0.000213	0.00151	CcSEcCtD
Paricalcitol—Arrhythmia—Doxorubicin—bone cancer	0.000212	0.0015	CcSEcCtD
Paricalcitol—Nausea—Cisplatin—bone cancer	0.00021	0.0015	CcSEcCtD
Paricalcitol—Alopecia—Doxorubicin—bone cancer	0.000209	0.00149	CcSEcCtD
Paricalcitol—Cough—Methotrexate—bone cancer	0.000208	0.00148	CcSEcCtD
Paricalcitol—Mental disorder—Doxorubicin—bone cancer	0.000208	0.00148	CcSEcCtD
Paricalcitol—Ill-defined disorder—Epirubicin—bone cancer	0.000207	0.00147	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—bone cancer	0.000206	0.00147	CcSEcCtD
Paricalcitol—Anaemia—Epirubicin—bone cancer	0.000206	0.00146	CcSEcCtD
Paricalcitol—Agitation—Epirubicin—bone cancer	0.000205	0.00146	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—bone cancer	0.000203	0.00144	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—bone cancer	0.000203	0.00144	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—bone cancer	0.000203	0.00144	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—bone cancer	0.000202	0.00144	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—bone cancer	0.000202	0.00144	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000201	0.00143	CcSEcCtD
Paricalcitol—Malaise—Epirubicin—bone cancer	0.000201	0.00143	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—bone cancer	0.0002	0.00142	CcSEcCtD
Paricalcitol—Nervousness—Doxorubicin—bone cancer	0.0002	0.00142	CcSEcCtD
Paricalcitol—Vertigo—Epirubicin—bone cancer	0.0002	0.00142	CcSEcCtD
Paricalcitol—Syncope—Epirubicin—bone cancer	0.0002	0.00142	CcSEcCtD
Paricalcitol—Leukopenia—Epirubicin—bone cancer	0.000199	0.00142	CcSEcCtD
Paricalcitol—Back pain—Doxorubicin—bone cancer	0.000199	0.00142	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—TP53—bone cancer	0.000198	0.00215	CbGpPWpGaD
Paricalcitol—Muscle spasms—Doxorubicin—bone cancer	0.000198	0.00141	CcSEcCtD
Paricalcitol—Palpitations—Epirubicin—bone cancer	0.000197	0.0014	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—bone cancer	0.000196	0.00139	CcSEcCtD
Paricalcitol—Loss of consciousness—Epirubicin—bone cancer	0.000196	0.00139	CcSEcCtD
Paricalcitol—Cough—Epirubicin—bone cancer	0.000194	0.00138	CcSEcCtD
Paricalcitol—Infection—Methotrexate—bone cancer	0.000193	0.00137	CcSEcCtD
Paricalcitol—Hypertension—Epirubicin—bone cancer	0.000192	0.00137	CcSEcCtD
Paricalcitol—Ill-defined disorder—Doxorubicin—bone cancer	0.000191	0.00136	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—bone cancer	0.000191	0.00135	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—bone cancer	0.000191	0.00135	CcSEcCtD
Paricalcitol—Arthralgia—Epirubicin—bone cancer	0.00019	0.00135	CcSEcCtD
Paricalcitol—Chest pain—Epirubicin—bone cancer	0.00019	0.00135	CcSEcCtD
Paricalcitol—Myalgia—Epirubicin—bone cancer	0.00019	0.00135	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—bone cancer	0.000189	0.00135	CcSEcCtD
Paricalcitol—Anxiety—Epirubicin—bone cancer	0.000189	0.00134	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—bone cancer	0.000189	0.00134	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000188	0.00134	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—bone cancer	0.000188	0.00134	CcSEcCtD
Paricalcitol—Discomfort—Epirubicin—bone cancer	0.000187	0.00133	CcSEcCtD
Paricalcitol—Malaise—Doxorubicin—bone cancer	0.000186	0.00132	CcSEcCtD
Paricalcitol—Dry mouth—Epirubicin—bone cancer	0.000186	0.00132	CcSEcCtD
Paricalcitol—Vertigo—Doxorubicin—bone cancer	0.000185	0.00132	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—bone cancer	0.000185	0.00132	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—bone cancer	0.000185	0.00131	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—bone cancer	0.000185	0.00131	CcSEcCtD
Paricalcitol—Confusional state—Epirubicin—bone cancer	0.000183	0.0013	CcSEcCtD
Paricalcitol—Palpitations—Doxorubicin—bone cancer	0.000182	0.0013	CcSEcCtD
Paricalcitol—Oedema—Epirubicin—bone cancer	0.000182	0.00129	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—bone cancer	0.000182	0.00129	CcSEcCtD
Paricalcitol—Loss of consciousness—Doxorubicin—bone cancer	0.000181	0.00129	CcSEcCtD
Paricalcitol—Infection—Epirubicin—bone cancer	0.000181	0.00128	CcSEcCtD
Paricalcitol—Cough—Doxorubicin—bone cancer	0.00018	0.00128	CcSEcCtD
Paricalcitol—Shock—Epirubicin—bone cancer	0.000179	0.00127	CcSEcCtD
Paricalcitol—Nervous system disorder—Epirubicin—bone cancer	0.000178	0.00127	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—bone cancer	0.000178	0.00127	CcSEcCtD
Paricalcitol—VDR—Gene Expression—EIF2S1—bone cancer	0.000177	0.00192	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000177	0.00126	CcSEcCtD
Paricalcitol—Skin disorder—Epirubicin—bone cancer	0.000177	0.00126	CcSEcCtD
Paricalcitol—Hyperhidrosis—Epirubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—bone cancer	0.000176	0.00125	CcSEcCtD
Paricalcitol—Arthralgia—Doxorubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—bone cancer	0.000175	0.00124	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—bone cancer	0.000175	0.00124	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000174	0.00124	CcSEcCtD
Paricalcitol—Discomfort—Doxorubicin—bone cancer	0.000173	0.00123	CcSEcCtD
Paricalcitol—Anorexia—Epirubicin—bone cancer	0.000173	0.00123	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—bone cancer	0.000173	0.00123	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—bone cancer	0.000173	0.00123	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—bone cancer	0.000172	0.00122	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—bone cancer	0.000171	0.00122	CcSEcCtD
Paricalcitol—Hypotension—Epirubicin—bone cancer	0.00017	0.00121	CcSEcCtD
Paricalcitol—Confusional state—Doxorubicin—bone cancer	0.00017	0.00121	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—bone cancer	0.000169	0.0012	CcSEcCtD
Paricalcitol—Oedema—Doxorubicin—bone cancer	0.000168	0.0012	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—bone cancer	0.000168	0.00119	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—bone cancer	0.000168	0.00119	CcSEcCtD
Paricalcitol—Infection—Doxorubicin—bone cancer	0.000167	0.00119	CcSEcCtD
Paricalcitol—Pain—Methotrexate—bone cancer	0.000166	0.00118	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000166	0.00118	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—bone cancer	0.000166	0.00118	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ENO2—bone cancer	0.000166	0.00179	CbGpPWpGaD
Paricalcitol—Nervous system disorder—Doxorubicin—bone cancer	0.000165	0.00117	CcSEcCtD
Paricalcitol—Insomnia—Epirubicin—bone cancer	0.000164	0.00117	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—bone cancer	0.000163	0.00116	CcSEcCtD
Paricalcitol—Paraesthesia—Epirubicin—bone cancer	0.000163	0.00116	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—bone cancer	0.000163	0.00116	CcSEcCtD
Paricalcitol—Dyspnoea—Epirubicin—bone cancer	0.000162	0.00115	CcSEcCtD
Paricalcitol—Somnolence—Epirubicin—bone cancer	0.000162	0.00115	CcSEcCtD
Paricalcitol—Anorexia—Doxorubicin—bone cancer	0.00016	0.00114	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—bone cancer	0.00016	0.00114	CcSEcCtD
Paricalcitol—Dyspepsia—Epirubicin—bone cancer	0.00016	0.00114	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—bone cancer	0.000159	0.00113	CcSEcCtD
Paricalcitol—Decreased appetite—Epirubicin—bone cancer	0.000158	0.00112	CcSEcCtD
Paricalcitol—Hypotension—Doxorubicin—bone cancer	0.000157	0.00112	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Epirubicin—bone cancer	0.000157	0.00112	CcSEcCtD
Paricalcitol—Fatigue—Epirubicin—bone cancer	0.000157	0.00111	CcSEcCtD
Paricalcitol—Pain—Epirubicin—bone cancer	0.000156	0.00111	CcSEcCtD
Paricalcitol—Constipation—Epirubicin—bone cancer	0.000156	0.00111	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—bone cancer	0.000154	0.0011	CcSEcCtD
Paricalcitol—VDR—Gene Expression—EZH2—bone cancer	0.000154	0.00167	CbGpPWpGaD
Paricalcitol—Body temperature increased—Methotrexate—bone cancer	0.000154	0.00109	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—bone cancer	0.000154	0.00109	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—DHFR—bone cancer	0.000154	0.00166	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000153	0.00109	CcSEcCtD
Paricalcitol—Insomnia—Doxorubicin—bone cancer	0.000152	0.00108	CcSEcCtD
Paricalcitol—Paraesthesia—Doxorubicin—bone cancer	0.000151	0.00107	CcSEcCtD
Paricalcitol—Dyspnoea—Doxorubicin—bone cancer	0.00015	0.00107	CcSEcCtD
Paricalcitol—Feeling abnormal—Epirubicin—bone cancer	0.00015	0.00107	CcSEcCtD
Paricalcitol—Somnolence—Doxorubicin—bone cancer	0.00015	0.00106	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Epirubicin—bone cancer	0.000149	0.00106	CcSEcCtD
Paricalcitol—Dyspepsia—Doxorubicin—bone cancer	0.000148	0.00105	CcSEcCtD
Paricalcitol—Decreased appetite—Doxorubicin—bone cancer	0.000146	0.00104	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000145	0.00103	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—bone cancer	0.000145	0.00103	CcSEcCtD
Paricalcitol—Urticaria—Epirubicin—bone cancer	0.000144	0.00103	CcSEcCtD
Paricalcitol—Pain—Doxorubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Paricalcitol—Abdominal pain—Epirubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Paricalcitol—Body temperature increased—Epirubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GNA11—bone cancer	0.000144	0.00156	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Methotrexate—bone cancer	0.000143	0.00102	CcSEcCtD
Paricalcitol—Asthenia—Methotrexate—bone cancer	0.000139	0.000991	CcSEcCtD
Paricalcitol—Feeling abnormal—Doxorubicin—bone cancer	0.000139	0.000986	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Doxorubicin—bone cancer	0.000138	0.000978	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—bone cancer	0.000137	0.000978	CcSEcCtD
Paricalcitol—Hypersensitivity—Epirubicin—bone cancer	0.000134	0.000953	CcSEcCtD
Paricalcitol—Urticaria—Doxorubicin—bone cancer	0.000134	0.00095	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—bone cancer	0.000133	0.000946	CcSEcCtD
Paricalcitol—Abdominal pain—Doxorubicin—bone cancer	0.000133	0.000946	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—bone cancer	0.000133	0.000945	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ENO2—bone cancer	0.000132	0.00143	CbGpPWpGaD
Paricalcitol—Asthenia—Epirubicin—bone cancer	0.00013	0.000928	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.00013	0.00141	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP3A4—bone cancer	0.00013	0.00141	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000129	0.0014	CbGpPWpGaD
Paricalcitol—Pruritus—Epirubicin—bone cancer	0.000129	0.000915	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—bone cancer	0.000129	0.000914	CcSEcCtD
Paricalcitol—Diarrhoea—Epirubicin—bone cancer	0.000124	0.000885	CcSEcCtD
Paricalcitol—Hypersensitivity—Doxorubicin—bone cancer	0.000124	0.000881	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—bone cancer	0.000124	0.000878	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—DHFR—bone cancer	0.000123	0.00133	CbGpPWpGaD
Paricalcitol—Rash—Methotrexate—bone cancer	0.000123	0.000871	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—bone cancer	0.000122	0.00087	CcSEcCtD
Paricalcitol—Headache—Methotrexate—bone cancer	0.000122	0.000866	CcSEcCtD
Paricalcitol—Asthenia—Doxorubicin—bone cancer	0.000121	0.000858	CcSEcCtD
Paricalcitol—Dizziness—Epirubicin—bone cancer	0.00012	0.000855	CcSEcCtD
Paricalcitol—Pruritus—Doxorubicin—bone cancer	0.000119	0.000846	CcSEcCtD
Paricalcitol—Vomiting—Epirubicin—bone cancer	0.000116	0.000822	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—bone cancer	0.000115	0.000821	CcSEcCtD
Paricalcitol—Diarrhoea—Doxorubicin—bone cancer	0.000115	0.000819	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GNA11—bone cancer	0.000115	0.00124	CbGpPWpGaD
Paricalcitol—Rash—Epirubicin—bone cancer	0.000115	0.000815	CcSEcCtD
Paricalcitol—Dermatitis—Epirubicin—bone cancer	0.000115	0.000815	CcSEcCtD
Paricalcitol—Headache—Epirubicin—bone cancer	0.000114	0.00081	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GSTP1—bone cancer	0.000111	0.00121	CbGpPWpGaD
Paricalcitol—Dizziness—Doxorubicin—bone cancer	0.000111	0.000791	CcSEcCtD
Paricalcitol—Nausea—Epirubicin—bone cancer	0.000108	0.000768	CcSEcCtD
Paricalcitol—Vomiting—Doxorubicin—bone cancer	0.000107	0.000761	CcSEcCtD
Paricalcitol—Rash—Doxorubicin—bone cancer	0.000106	0.000754	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—bone cancer	0.000106	0.000754	CcSEcCtD
Paricalcitol—Headache—Doxorubicin—bone cancer	0.000105	0.000749	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP3A4—bone cancer	0.000104	0.00113	CbGpPWpGaD
Paricalcitol—Nausea—Doxorubicin—bone cancer	0.0001	0.000711	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GSTP1—bone cancer	8.9e-05	0.000964	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTP1—bone cancer	8.44e-05	0.000915	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	8.33e-05	0.000903	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NDUFA12—bone cancer	5.92e-05	0.000641	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—bone cancer	5.77e-05	0.000625	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NT5C3A—bone cancer	4.9e-05	0.000532	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—bone cancer	4.61e-05	0.0005	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ENO2—bone cancer	2.15e-05	0.000233	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—DHFR—bone cancer	1.99e-05	0.000216	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GNA11—bone cancer	1.86e-05	0.000202	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTP1—bone cancer	1.44e-05	0.000157	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—bone cancer	7.48e-06	8.11e-05	CbGpPWpGaD
